TALWIN SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PENTAZOCINE (PENTAZOCINE LACTATE)

から入手可能:

PFIZER CANADA ULC

ATCコード:

N02AD01

INN（国際名）:

PENTAZOCINE

投薬量:

30MG

医薬品形態:

SOLUTION

構図:

PENTAZOCINE (PENTAZOCINE LACTATE) 30MG

投与経路:

INTRAMUSCULAR

パッケージ内のユニット:

1ML

処方タイプ:

Narcotic (CDSA I)

治療領域:

OPIATE PARTIAL AGONISTS

製品概要:

Active ingredient group (AIG) number: 0108852001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2019-11-21

製品の特徴

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TALWIN
(Pentazocine Lactate Injection, USP)
30 mg/mL
Sterile Solution
Narcotic Analgesic
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Submission Control No.: 213124
Date of Revision:
April 17, 2018
_Product Monograph _
_N_
_Talwin _
_Page 2 of 30 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
................................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
PATIENT MEDICATION INFORMATION
...............................